雷鲁戈利克斯

雷鲁戈利克斯（CAS 737789-87-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.Relugolix is an orally administered, small molecule antagonist of gonadotropin releasing hormone (GnRH) that effectively blocks androgen production and is used to treat advanced prostate cancer. Relugolix therapy may be associated with a low rate of serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent acute liver injury.

同义词与商品名

Relugolix; 737789-87-6; TAK-385; Orgovyx; TAK 385; TAK385; P76B05O5V6; DTXSID40224167; MYFEMBREE COMPONENT RELUGOLIX; relugolixum; RefChem:57784; DTXCID40146658; MFCD25976856; C29H27F2N7O5S; CHEMBL1800159; Relugolix [USAN:INN]

GHS 危害分类

Reported hazard statements	H360 (20%), H361 (60%), H371 (40%), H373 (20%), H411 (20%)

H360 (20%): May damage fertility or the unborn child [Danger Reproductive toxicity]

H361 (60%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

公开数据库对它的描述

Relugolix · CAS 737789-87-6 · C29H27F2N7O5S. UNII P76B05O5V6. LogP: 1.69.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。